STOCKS TELEGRAPH

Tag: NYSE: PFE

Are The Current Prices Weighing On Pfizer And BioNTech, When To Buy These Stock?

Without significant reservations, the vaccine from Pfizer and BioNTech was approved for review by the FDA. All the basic parameters of the vaccine have been verified by the Commission that approved the application, including that it is 95 percent successful. Furthermore other significant aspects of the research were revealed. That the vaccine triggers defense at the first injection, however a course of two injections is necessary to get immunity. After the first treatment, it is 52 percent successful (with the minimum FDA requirements of 50 percent).

Cases of severe side effects, such as paralysis of the facial nerve and swelling of the lymph node, occur, but within the normal vaccine initiation figures. There were also cases of COVID-19 after vaccination, but all of them fall within a period of up to two weeks after the injection, that is, before the immunity acquired was established. Neither the vaccine nor COVID-19 were associated with patient deaths (6 episodes in total). Both of them occurred in chronic disease subjects.

During the analysis of the certification application, all such data will be checked again. In the coming weeks, a decision could be taken, but the market is betting it will be unambiguously positive. Pfizer and BioNTech shares have risen in recent sessions. Starting on Monday, the former rose by 3.74 percent in total while the later stock gained 2.34 percent. The rise comes in the midst of a report by a number of investment firms of target prices for these stocks.

In our view, shares of both vaccine developers have now reached their equal amount. Pfizer has the potential to fall by at least 5 percent in the medium term and up to 15 percent with a likely correction in the indexes. At a drop to $40, and at a rapid breakout of this level-from $37 each, we suggest entering the company’s shares. BioNTech has a more substantial speculative overhang, with its shares being able to change by 20% even with a neutral external backdrop in the coming months.

In Wednesday session, Pfizer stock dropped by -1.67% while that of BioNTech was down -4.14%.

December 10, 2020
Is Pfizer (PFE) Stock Is Better Than Of Moderna (MRNA)?

In December, Pfizer Inc (PFE) won’t be able to produce up to half of the new vaccine. The organization acknowledged that it is facing logistics issues. Customers will receive just 50 million out of the previously expected 100 million doses. The production goal remains the same for the whole of next year as Pfizer plans to ship about 1 billion doses. Even the closest rival Moderna Inc (MRNA) is adjusting the sales targets. Thus, it has been announced that the company will ship 100-125 million doses in the first quarter of 2021. This brings into question the achievement of the target of 500 million doses for the year as a whole and suggests implicitly that capability issues remain. The obstacles to mass delivery of Pfizer and Moderna vaccines are similar as they must be transported and stored at temperatures no higher than -20 and -70 degrees Celsius, respectively.

The market responded to this news ambiguously. In the last week, though Moderna shares increased about 20 percent, Pfizer shares rose just 8 percent. Once again, players prefer a more costly and less mass-produced, but more compact, vaccine. In part, this disparity in valuation can be explained by the fact that in the United States, the number of firms able to assist in the delivery of drugs multiplied. This involves meat producers with cooling systems and Uber, which has formally appealed to the authorities to allow taxi drivers the right to distribute the vaccine to hospitals and pharmacies in need. Pharmacy chains also volunteered to open vaccination points, and some are already included in the US state program.

The unhealthy panic around the Moderna Inc (MRNA) stock is not justified in our view. The prices of their shares have increased 1.8 times in a month, while retaining unchanged distribution plans, and are now at least one third more expensive than their equilibrium value.

Pfizer Inc (PFE), which is less reliant on its sales from vaccinations, is undervalued. In the coming months, the shares have a potential of up to 5 percent. We suggest buying them on a drawdown when the price hits $37 a share, anticipating a short-term correction in the market.

December 7, 2020
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) buzzing as the U.K permits vaccine use

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) just revealed the Regulatory Body for Medicines & Healthcare Goods (MHRA) in the U.K. has given temporary permission for emergency use of their mRNA (BNT162b2) vaccine against COVID-19. This constitutes the first sanction for immediate use after a Phase 3 worldwide trial of a vaccine to combat the pandemic. Pfizer and BioNTech expect more regulatory decisions across the globe in the coming days and weeks and can supply vaccine doses following possible regulatory authorizations or approvals. The U.K. delivery priority would be set according to the groups identified in the Joint Committee on Vaccination and Immunisation guidelines (JCVI).

This year, Pfizer and BioNTech signed a partnership with the U.K. that once approved for emergency use, to provide 30 million doses of BNT162b2 mRNA-based vaccine. In early October, the deal was expanded to 40 million doses. The 40 million doses will be distributed in phases across 2020 and 2021 to ensure an equal distribution of vaccinations across geographies of contracts executed. Now that the vaccine is approved in the United Kingdom, businesses will take prompt steps to distribute the vaccine doses. It is predicted that the first doses will arrive in the U.K. With absolute distribution fulfillment expected in 2021, in the coming days.

The firms have applied with the U.S. for Emergency Use Permission. Following rolling applications to the European Medicines Agency (EMA) and many other regulatory bodies around the world, the Food and Drug Administration (FDA) has applied the final Conditional Marketing Authorization Application (CA).

December 2, 2020
Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United States and Europe, which has been shown to be more than 94% successful in advanced clinical trials.

Pfizer Inc (PFE) gained 2.90 percent to $38.31 and BioNTech SE (BNTX) added 12.96 percent to close at $124.24 on Monday. The drug manufacturing companies were able to receive regulatory approvals in the United Kingdom and the United States for their 95 percent successful vaccine candidate within a few days.

Novavax Inc (NVAX) saw a rise of 10.99 percent to conclude the trading at $139.50. Stock of soared, while the biotechnology company again postponed the launch in the United States of a Phase III clinical trial of its Covid experimental vaccine, but cited a possible start-up in the coming weeks.

S&P Global Inc (SPGI) was up 2.99 percent to $351.78. As expected, it announced IHS Markit’s acquisition of $44 billion in shares, the biggest merger and value acquisition since the beginning of the year. The total capitalization of IHS Markit is $37 billion.

Airbnb is looking for a $30 billion to $33 billion valuation for its Wall Street IPO. Food distribution player, DoorDash, with its more than tripled sales in nine months and first quarterly profit, is also greedy for its IPO with a cap from $25 billion to $28 billion. Both companies are planning to join the Wall Street in mid-December.

Netflix Inc (NFLX) slipped -0.13 percent to $490.70 in the last session. The video streaming service is expected to begin disclosing revenue of more than GBP 1 billion from British subscribers to tax authorities in the UK, according to the Guardian. The Guardian claims that Netflix’s decision could place pressure on other U.S. tech giants such as Google or Amazon, who are currently preventing such reporting by optimizing their taxation.

December 1, 2020
Pfizer Inc. (NYSE: PFE) set to roll out 50 million coronavirus vaccines by the end of 2020

Drug-maker giant Pfizer Inc. (NYSE: PFE) shares jumped 14% after it said that preliminary analysis showed 90% efficacy of its coronavirus vaccine.

It was called a “great day for science & humanity,” by development companies Pfizer and BioNTech.

Their vaccine was tested in six countries on 43,500 individuals and no safety issues were posed.

In response to a clear end to the US election, stocks, already bolstered, poured on profits and the FTSE 100 soared 5 percent.

But businesses benefiting from it dived as airlines, hotels, and others hit hardest by the pandemic jumped by up to 53 percent.

Similar gains to those seen in London were made by other markets in Europe. And the Dow Jones and S&P 500 opened 5.6% and 3.6% higher, respectively, in the US.

It is very unusual for stocks to leap by such wide margins, and in the case of the UK, on the market’s best day since March, the FTSE 100 added £82bn to the value of its shares.

Companies expect to apply by the end of the month for emergency permission to use the vaccine.

There is still a lot of work to be done, but the news was warmly embraced by scientists who are anticipating that by spring life could be back to normal.

A vaccination is seen as the only way to break out of the constraints that have been placed in the daily lives, alongside improved therapies.

In the final stages of study-known as a phase 3 trial-there are around a hundred, but this is the first to produce any results.

In order to train the immune system, it uses an entirely experimental technique-which includes injecting part of the genetic code of the virus.

Previous studies have shown that the body is being prepared to generate both antibodies and another element of the immune response against coronavirus called T-cells.

This drug is injected in two doses, three weeks apart. Studies in the United States, Germany, Brazil, Argentina, South Africa, and Turkey have shown that 90% of safety is obtained 7 days after the second dose.

Pfizer in the meantime plans to produce 50 million doses by the end of this year and about 1.3 billion by the end of next year.

November 10, 2020
BioNTech (NASDAQ: BNTX) And Pfizer Starts Rolling Submission For COVID-19 Vaccine Candidate

BioNTech SE (NASDAQ: BNTX) and Pfizer, Inc. (NYSE: PFE) has announced today that they have started the rolling submission to the European Medicines Agency (EMA) to get approval for the COVID-19 vaccine candidate BNT162b2. European Medicines Agency (EMA) took the decision of review after seeing the promising preliminary results from pre-clinical and early clinical studies in adults.

The preclinical study disclosed that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2, the virus which caused the COVID-19 disease. The study proved that the combination of antibody and T cell are important tools against the novel coronavirus.

Pfizer and BioNTech have disclosed that they are planning to work closely with the EMA’s Committee for Medicinal Products for Human Use (CHMP) to finalize the rolling review process to enable the final Marketing Authorization Application (MAA). In rolling review, CHMP has started evaluating data generated in pre-clinical trials.

The term “rolling review” means that the regulatory authority has begun evaluating the first batch of data on the vaccine. In the rolling review of BNT162b2, the European Medicines Agency (EMA) will evaluate the real-time data which the company gathered after giving doses to patients in different trials. Instead of submitting all that data at once, it is better to start the rolling review so that the company will be able to know where its vaccine candidate stands.

Shares of BioNTech (NASDAQ: BNTX) traded up 6.49% as it gained +5.24 at $85.94 during the trading session of Tuesday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $12.52 and a high range of $105.00. It has moved up 586.15% from its 52-weeks low and moved down -18.15% from its 52-weeks high. This company market capitalization has remained high, hitting $18.96 billion at the time of writing.

On the other hand, Pfizer Inc. (NYSE: PFE) shares were trading down 0.20% as it lost -0.08 during at the time of writing on Tuesday. Pfizer Inc. share price went from a low point around $27.88 to briefly over $ in p40.97ast 52 weeks, though shares have since pulled back to $36.67. PFE market cap has remained high, hitting $204.16 Billion at the time of writing.

The BNT162b2 vaccine candidate is based on the proprietary mRNA technology of BioNTech. It is supported by Pfizer’s global vaccine development and manufacturing capabilities. BioNTech aimed to develop a potential vaccine at this period of uncertainty where COVID-19 is spreading all around the world.

October 6, 2020
Is Pfizer Inc. (NYSE: PFE) A Good Investment?

Shares of Pfizer Inc. (NYSE: PFE) traded up 2.61% after gaining +0.94 on Monday as it may be the first to disclose the late-stage study result from its trials with partner BioNTech SE. Pfizer Inc. is currently conducting one of the most advanced trials of a vaccine for novel coronavirus.

It has commenced the Phase 2/3 study of BNT162b2, a most advanced coronavirus vaccine candidate in July. Almost 30,000 participants were enrolled in the trial who received two doses of the vaccine candidate.

Pfizer CEO Albert Bourla revealed that the FDA committee will gather to discuss vaccines on Oct 22. CEO said that the company has a deep understanding of this matter and it will be able to present the efficacy data of Phase 3 before the end of October.

He said that the company is not bound to any deadline. Albert Bourla said that FDA is searching for companies to review their vaccines that are at least 50% effective. Pfizer is hoping for a better result as its Phase 3 trial with 30,000 people is almost completed.

Goldman Sachs labeled this a vaccine trade as the investors were attracting towards stocks that were developing a vaccine or any treatment of diseases and they dumped the stock soon after hearing the good news. The same thing happened with Gilead Sciences as its shares tumbled down after it has got the regulatory approval for its antiviral medicine of COVID-19.

Pfizer Inc. (NYSE: PFE) share price went from a low point around $27.88 to briefly over $40.97 in the past 52 weeks, though shares have since pulled back to $37.01. Pfizer Inc. has moved up 32.75% from its 52-weeks low and moved down -9.67% from its 52-weeks high. Pfizer Inc.’s market cap has remained high, hitting $203.27 billion at the time of writing. If we look at its liquidity, it has a current ratio of 1.40.

Pfizer Inc and BioNTech SE have recently disclosed that they striving to secure the approval of the US FDA to expand the late-stage clinical trial of their COVID-19 vaccine. Earlier, Pfizer has enrolled the 30,000 participants in the trial but now it is looking for the trial which will enroll 44,000 volunteers as the company is trying to add the young population in the late-stage study.

Previously, the US Government has revealed that it would pay $1.95 billion to companies for the supply of 100 million doses of vaccine if it received regulatory approval. CEO Pfizer also disclosed that the company has invested $1.5 billion for the development of a vaccine and if the trial is not successful it is painful for the company.

September 15, 2020